



**FOR IMMEDIATE RELEASE:**

## **Bioniche Management Proxy Circular for 2013 Annual and Special Meeting Now Available**

**BELLEVILLE, ON, October 18, 2013** – Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has posted on the Company's website ([www.Bioniche.com](http://www.Bioniche.com)), on SEDAR ([www.sedar.com](http://www.sedar.com)), and on [www.ASX.com.au](http://www.ASX.com.au) the management proxy circular relating to the Annual and Special Meeting of Bioniche Life Sciences Inc. Shareholders. The notice of meeting and management information circular (the "Circular") has been mailed to all shareholders of record as at September 9, 2013.

The Annual and Special Meeting of Shareholders will be held at 4:00 p.m. Eastern on November 5, 2013 in the Park Ballroom at the Travelodge Hotel, 11 Bay Bridge Road, Belleville, Ontario, Canada. All shareholders are encouraged to vote in person or by proxy. Details regarding how to vote are contained in the Circular.

The Company has retained Laurel Hill Advisory Group ("Laurel Hill") to act as proxy solicitation agent and to respond to inquiries from Bioniche shareholders. Laurel Hill may be contacted by telephone at 1-877-452-7184 toll-free in North America and at 416-304-0211 for collect calls outside of North America, or by email at [assistance@laurelhill.com](mailto:assistance@laurelhill.com).

### **About Bioniche Life Sciences Inc.**

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets worldwide. The fully-integrated company employs more than 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and One Health. The Company's primary goal is to develop and commercialize products that advance human or animal health and increase shareholder value.

For more information, please visit [www.Bioniche.com](http://www.Bioniche.com).

*Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.*

### **For further information, please contact:**

Jennifer Shea, Vice-President, Communications, Investor & Government Relations

Bioniche Life Sciences Inc.

Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058

Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097

[Jennifer.Shea@Bioniche.com](mailto:Jennifer.Shea@Bioniche.com)